NIH Guide: Weekly Index for January 15, 2021

Funding Opportunities

• Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
  (PA-21-110)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): See FOA
• Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed)
  (PAR-21-062)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
• NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
  (PAR-21-082)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022; September 13, 2022; January 13, 2023; May 13, 2023; September 14, 2023; January 13, 2024
• NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
  (PAR-21-083)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022; September 13, 2022; January 13, 2023; May 13, 2023; September 14, 2023; January 13, 2024
• NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00 Independent Clinical Trial Not Allowed)
  (PAR-21-108)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Standard dates apply. The first application due date is April 8, 2021.
• Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
  (PAR-21-109)
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Center for Complementary and Integrative Health
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Standard dates apply. The first application due date for this FOA is June 16, 2021.
• NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)
  (PAR-21-118)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)
  (PAR-21-119)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
  (PAR-21-148)
  National Institute for Occupational Safety and Health
  Application Receipt Date(s): Standard dates apply; All applications are due by 5:00 PM local time of applicant organization.
• Infectious Etiology of Alzheimer's Disease (R01 Clinical Trial Optional)
  (RFA-AG-21-034)
  National Institute on Aging
  Application Receipt Date(s): March 31, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)
  (RFA-AI-20-077)
  National Institute of Allergy and Infectious Diseases
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): June 4, 2021
• Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)
  (RFA-AI-20-078)
  National Institute of Allergy and Infectious Diseases
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): June 18, 2021
• HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed)
  (RFA-DA-21-020)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): March 31, 2021 No late applications will be accepted for this Funding Opportunity Announcement
• HEAL Initiative: HEALthy Brain and Child Development Study (U01 - Clinical Trial Not Allowed)
  (RFA-DA-21-021)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): March 31, 2021 No late applications will be accepted for this Funding Opportunity Announcement
• HEAL Initiative: HEALthy Brain and Child Development Consortium Administrative Core (U24 - Clinical Trial Not Allowed)
  (RFA-DA-21-022)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): March 31, 2021 No late applications will be accepted for this Funding Opportunity Announcement
• HEAL Initiative: HEALthy Brain and Child Development Data Coordinating Center (U24)
  (RFA-DA-21-023)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): March 31, 2021 No late applications will be accepted for this Funding Opportunity Announcement
• HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional)
  (RFA-DA-21-029)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): March 31, 2021
• HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)
  (RFA-DA-21-030)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): March 31, 2021
• Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)
  (RFA-DK-21-001)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): See FOA
• BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
  (RFA-EY-21-001)
  National Eye Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): May 3, 2021; October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023
• Renewal - Elucidating the Sensorial and Functional Characteristics of Compositionally Different and Differently Aged Topical Formulations (U01) Clinical Trial Required
  (RFA-FD-21-021)
  Food and Drug Administration
  Application Receipt Date(s): March 18, 2021, by 11:59 PM Eastern Time.
• HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial - Clinical Sites (UG1 Clinical Trial Required)
  (RFA-HD-21-031)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): March 30, 2021
• HEAL Initiative: Data Coordinating Center for the Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial (U24 Clinical Trial Required)
  (RFA-HD-21-032)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): March 30, 2021
• INTUIT-PC: Improving Nonsurgical Treatment of Urinary Incontinence among women in Primary Care: Dissemination and Implementation of PCOR Evidence (U18)
  (RFA-HS-21-001)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): March 24, 2021 All applications are due by 5:00 PM local time of applicant organization.
• HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
  (RFA-MH-21-145)
  National Institute of Mental Health
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): March 18, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
• Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional)
  (RFA-TR-21-008)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): April 19, 2021, All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)
  (RFA-TR-21-010)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): April 13, 2021, September 13, 2021, January 12, 2022